Study to Evaluate the Safety, Tolerability, and Efficacy of LX7101 in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension

Inclusion Criteria:

- Adults ≥18 years of age

- Documented diagnosis of POAG or OHT, in both eyes

- Willing and able to provide written informed consent

Exclusion Criteria:

- History of any form of glaucoma in either eye, other than POAG

- Subjects who are unwilling or unable to discontinue contact lens wear prior to and
during study

- History of ocular trauma in either eye <6 months prior to Screening

- History of ocular infection or ocular inflammation in either eye <3 months prior to
Screening

- History of chronic or recurrent severe inflammatory eye disease, any severe ocular
pathology, or clinically relevant or progressive retinal diseases in either eye

- Clinically relevant, severe central visual field loss, or documented significant
progression of a visual field defect within 6 months prior to Screening in either eye

- Use of any ocular hypertensive medications (if applicable), in either eye, during the
washout period and for the duration of the study

- Use of any glucocorticoid medications <2 weeks prior to Screening and throughout the
duration of the study

- Use of any medication or substance on a chronic basis which has not been taken at a
stable dose for at least 30 days prior to Screening

- Use of any nondiagnostic, topical, ophthalmic preparations, in either eye, other than
artificial tears

- The presence of any concurrent condition or clinically significant laboratory
findings at Screening that may interfere with any aspect of safety, study conduct, or
interpretation of results

- Women who are pregnant or breast feeding

- Inability or difficulty instilling eye drops